Tag: peptide

What Kind Of Peptide Is TB 500?

TB-500 is a synthetic peptide of the naturally occuring healing protein present in about all human and mammalian cells known as Thymosin Beta 4 (TB4). TB 500 is thought to have beneficial effects on wound healing, injury recovery, flexibility, and inflammation. Research indicated the effects of TB 500 are on blood cell and blood vessel development, cellular differentiation, and cell migration. The healing capability is due in large from the peptide’s regulation of actin, a cell building protein essential to healing and wound repair.

TB 500 is produced in the thymus gland and is found in high concentrations in wound fluids. Research demonstrates it has wound healing properties in addition to healing and repair of skin, cornea, and heart.

TB 500 is a naturally occurring peptide also found in high concentrations in blood platelets. TB-500 peptides for research are not growth factors; rather major actin regulating protein peptides. TB 500 plays an important role in protection, regeneration and remodeling of injured and/or damaged tissues. The gene that codes for Thymosin Beta-4 was noted in a study to be one of the first to be stimulated after an incident of injury.

Present in almost all human and animal cells, Thymosin Beta 4 is naturally occurring wound healing peptide. TB 500 , a synthetically made version of TB4 that facilitates comparable healing and recovery by helping building new blood vessels, muscle tissue fibers, blood cells, and facilitating cell migration. For a stressed and injured person, TB 500 can offer an extremely desirable wound healing effects.

No Horsing Around

TB-500 is a synthetic version of Thymosin Beta 4, a protein peptide that occurs naturally in the bodies of both animals and humans. Although TB-500 is available for research purposes, it is commonly used by many veterinarians who conduct clinical trials using TB-500 on horses. It is used to help promote healing from injury and reduce recovery time.

Dr. Allan Goldstein formulated thymosin alpha 1, in order to increase immune cell activity and subsequently thymosin bta 4 or TB-500, in order to accelerate healing and wound repair in animals, such as horses and ?

In racehorses TB 500 has shown significant reductions of inflammation and the inhibition or reduction of adhesions from injury.

The human use of thymosin began in 1974, with the first reported case being a young girl who was injected with thymosin due to a non functioning thymus gland. Since then, an increasing number of athletes and biohackers have been using thymosin all for the very same reasons of repair, reduction of inflammation and to speed up recovery.

WHAT IS THYMOSIN BETA 4?

Thymosin is a hormone secreted from the thymus. Its primary function is to stimulate the production of T cells, which are an important part of the immune system. Thymosin also assists in the development of B cells to plasma cells to produce antibodies. The predominant form of thymosin, thymosin beta 4, is an actin, a cell building protein. One of the main mechanisms of action of Thymosin Beta-4 is its regulation of Actin. This cell-building protein is an essential component of cell structure and movement which leads to its role in tissue repair. Tβ 4 has been found to play an important role in protection, regeneration, and remodeling of injured or damaged tissues. After an injury, Tβ 4 is released by platelets and numerous other types of cells to protect the most damaged cells and tissues and to reduce inflammation and microbial growth.

Benefits of Thymosin beta 4:

  • Calms muscle spasms
  • Enhances muscle tone
  • Increased exchange of substances between cells
  • Encourages tissue repair
  • Stretches connective tissue
  • Helps maintain flexibility
  • Reduced inflammation of tissue in joints
  • Encourages the growth of new blood cells in tissue
  • Increased endurance and strength
  • Prevents the formation of adhesions and fibrous bands in muscles, tendons, and ligaments

Recent studies have revealed that the first gene to be upregulated after an injury is a Tβ4 gene. As the body begins the recovery process, Tβ4 aids in the creation of new vessels in the injured area, which carry blood, nutrients, and reparative substances to the site. Tβ4 also has anti-inflammatory properties and works to decrease the amount of inflammatory substances, called cytokines. Inflammation plays a large role in many of the symptoms associated with a number of other conditions (i.e., Lyme disease, CFS, FM, autoimmune diseases, infections, etc.), making the potential impact of Tβ4 quite extensive.

The discovery of the role of Tβ4 in the process of immune regulation has lead to its use as a valuable therapeutic agent. Tβ4 has been used in the treatment of HIV, AIDS, Influenza, colds, and various infections. It has been utilized in the management of various inflammatory conditions, as well as part of treatment following a heart attack due to its cardio and neuroprotective effects.

Tβ4 is very well tolerated and has not been found to cause any significant side effects. It can be taken on its own or in conjunction with an existing therapy, making it a versatile and valuable peptide.

SCIENTIFIC STUDIES, CLINICAL TRIALS AND EPITALON RESULTS

EPITALON DESCRIPTION
Epitalon is derived from Epithalamin (Epithalamine), a naturally occurring polypeptide in the body, which is produced in pineal gland. A very valuable and unique main property of Epitalon is its ability to increase telomerase activity in somatic cells. This helps cells reproduce telomeres, which are the essential “protective parts” of our DNA, which eventually results in a slowdown in the aging process.

In addition, scientific studies have also shown other great possible benefits of Epitalon as prevention of cancer and age-related diseases, restoration and normalization of melatonin levels, promotion of deeper sleep and strong anti-oxidant properties. Epitalon is patented by its discoverer Professor Khavinson and was approved for general use in Russia in 1990 and has since been used in gerontology. Many scientific studies and clinical trials of Epitalon have been conducted in both animals and humans, and no adverse side effects have ever been reported to date.

MECHANISM OF ACTION OF EPITALON
Telomerase activator peptide Epitalon directly stimulates cells in the body to produce a telomerase enzyme, that renew and extends telomeres at the ends of chromosomes. This ultimately leads to a slowing of the aging of cell populations, and the aging of cell populations correlate with the overall physical aging of an organism. Clinical studies conducted with Epitalon have shown that administration of Epitalon to mammals has not only reversed the symptoms of aging but also reversed many age-related diseases. Epitalon has also been shown to help restore and normalize melatonin production by the pineal gland, as well as restoring the normal circadian rhythm of cortisol production, both of which result in better sleep at night.

DNA & CHROMOSOMES
DNA (Deoxyribonucleic acid) is a molecule composed of 2 polynucleotide chains that coil around each other to form a double helix carrying genetic instructions for the development, functioning, growth and reproduction of all known organisms and many viruses. DNA and RNA (Ribonucleic acid) are nucleic acids. Alongside proteins, lipids and complex carbohydrates (polysaccharides), nucleic acids are one of the four major types of macromolecules that are essential for all known forms of life.

Chromosome is a DNA molecule with part or all of the genetic material (genome) of an organism: Within eukaryotic cells (animals, plants, fungi and protists), DNA is organized into long structures called chromosomes. Before typical cell division, these chromosomes are duplicated in the process of DNA replication, providing a complete set of chromosomes for each daughter cell. Eukaryotic organisms store most of their DNA inside the cell nucleus as nuclear DNA, and some in the mitochondria as mitochondrial DNA or in chloroplasts as chloroplast DNA.

TELOMERE
Telomere is important region of repetitive nucleotide sequences at each end of a chromosome, which protects the end of the chromosome from deterioration or from fusion with neighboring chromosomes. However, as a result of each cell division, the ends of the telomeres are shortened: During chromosome replication, the enzymes that duplicate DNA cannot continue their duplication all the way to the end of a chromosome, so in each duplication the end of the chromosome is shortened (this is because the synthesis of Okazaki fragments requires RNA primers attaching ahead on the lagging strand). This means, each cell division (each time a cell undergoes mitosis), the telomeres on the ends of each chromosome again shorten. After many divisions, the telomeres reach a critical length, resulting in the cell eventually losing its ability to divide further to replace worn, damaged or diseased cells. Further cell division becomes impossible and the cell becomes senescent. At this point, the cell reached its so-called Hayflick limit.

THE HAYFLICK LIMIT
The Hayflick limit, or Hayflick phenomenon, is the number of times a normal human cell population will divide before cell division stops. The concept of the Hayflick limit was advanced by American anatomist Leonard Hayflick in 1961, at the Wistar Institute in Philadelphia, Pennsylvania, United States. Hayflick demonstrated that a normal human fetal cell population will divide between 40 and 70 times in cell culture before entering a senescence phase. The aging of cell populations appears to correlate with the overall physical aging of an organism.

Hayflick was also the first to report that only cancer cells are immortal. Cellular senescence does not occur in most cancer cells due to expression of an enzyme telomerase, when telomerase extends telomeres / preventing the telomeres of cancer cells from shortening and by this way giving them infinite replicative potential. One of the proposed treatment for cancer is the usage of telomerase inhibitors in the cancer cells, that would prevent the restoration of their telomeres, and allows the cancer cells to die like other body cells.

TELOMERASE
Telomerase is a ribonucleoprotein that adds a species-dependent telomere repeat sequence to the 3′ end of telomeres. It is a reverse transcriptase enzyme that carries its own RNA molecule (e.g., with the sequence 3′-CCCAAUCCC-5′ in Trypanosoma brucei) which is used as a template when it elongates telomeres. Telomerase is active in gametes and most cancer cells, but is normally absent from, or at very low levels in, most somatic cells.

Telomerase restores short bits of DNA known as telomeres, which are otherwise shortened when a cell divides via mitosis. In normal circumstances, where telomerase is absent, if a cell divides recursively, at some point the progeny reach their Hayflick limit, which is believed to be between 40–70 cell divisions. At the limit the cells become senescent and cell division stops.

But Telomerase allows each offspring to replace the lost bit of DNA, allowing the cell line to divide without ever reaching the limit – allowing senescent cells that would otherwise become postmitotic and undergo apoptosis to exceed the Hayflick limit and become potentially immortal, as is often the case with cancerous cells.

Embryonic stem cells express telomerase, which allows them to divide repeatedly and form the individual. In adults, telomerase is highly expressed only in cells that need to divide regularly, especially in male sperm cells but also in epidermal cells, in activated T cell and B cell lymphocytes, as well as in certain adult stem cells, but in the great majority of cases somatic cells do not express telomerase.

PINEAL GLAND
The pineal gland is a small endocrine gland in the brain of most vertebrates. It is located in the epithalamus, near the center of the brain, between the two hemispheres, tucked in a groove where the two halves of the thalamus join. The pineal gland is one of the neuroendocrine secretory circumventricular organs in which there does not exist the blood–brain barrier at the capillary level.

The primary function of the pineal gland is to produce Melatonin, that has various functions in the central nervous system, the most important of which is to help modulate sleep patterns. The pineal gland also produces polypeptide Epithalamin, that stimulates cells in the body to produce a telomerase enzyme, that extends telomeres at the ends of chromosomes in their DNA. This ultimately leads to a slowing of the aging of cell populations.

EPITALON HISTORY
Epitalon was discovered and developed by the Russian scientist and gerontologist Professor, Doctor of Medical sciences Vladimir Khavinson of St. Petersburg Institute of Bioregulation and Gerontology, whose research is focused on the development of peptide preparations used to restore function in various organs in order to prevent and reverse the aging process. Epitalon was identified as active component of a bovine pineal gland extract (known as Epithalamin).

Low-molecular peptides isolated from pineal gland and Epithalamin of animals were studied in different biologic models. Most all performed scientific studies and clinical trials of Epitalon and Epithalamin have been conducted just by already mentioned St. Petersburg Institute of Bioregulation and Gerontology in Russia, primarily overseen by Professor Vladimir Khavinson, who has been involved in this research already for over 35 years, and has merit not only in the discovery of epitalon, but also in its highly advanced scientific and clinical review. Throughout this time, Epitalon has been extensively investigated in animal and human clinical trials and today is one of the best scientifically investigated peptides.

SCIENTIFIC STUDIES, CLINICAL TRIALS AND EPITALON RESULTS
Scientific studies in animals:

An in vivo study in aging mice found that epitalon treatment significantly reduced the incidence of chromosomal aberrations, both for wild-type mice and for mice characterized by an accelerated aging phenotype, which is consistent with increases in telomere length.

Another study in aging rats found that epitalon increased the activities of the antioxidant enzymes superoxide dismutase, glutathione peroxidase, and glutathione-S-transferase. In male rats, epithalamin increased total antioxidant capacity by 36% and superoxide dismutase (SOD, a powerful endogenous antioxidant) by 19%. Oxidative stress, which occurs when the body has a deficit in antioxidants to counteract the effects of free radicals (damaging molecules that are missing electrons), plays a causative role in many diseases, including heart disease, cancer, diabetes, and even neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases. One of the most potent endogenous antioxidants produced by the body is Melatonin. Epitalon’s antioxidant effects are thought to be in part due to its ability to stimulate Melatonin production as well as mechanisms other than through the action of Melatonin.

Epitalon reduced the number of spontaneous tumors and the number of metastases in mice that did develop spontaneous tumors in an experiment on one-year-old female C3H/He mice, and is speculated to have oncostatic and anti-metastatic properties.

In a study of chickens subjected to neonatal hypophysectomy and subsequent maturation, epitalon promoted the recovery of the morphological structures of the thymus, as well as the structure and function of the thyroid gland. Epitalon appears to increase the proliferation of lymphocytes in the thymus, putatively increasing production of interferon gamma by T-cells. Another study in aging rats demonstrated extension of life span for rats subjected to constant illumination or to a natural light regimen typical of northern regions.

Scientific studies in humans:

In human clinical studies, epitalon and epithalamin both significantly increased telomere lengths in the blood cells of patients of ages 60-65 and 75-80, and their efficacy was comparable to one another.

Epitalon and epithalamin appear to restore melatonin secretion by the pineal gland in both aged monkeys and humans.

A human clinical trial conducted on a sample of retinitis pigmentosa patients found that epitalon produced a positive clinical effect in 90% of cases in the treated group.

In another human clinical trial conducted on a sample of pulmonary tuberculosis patients, epitalon did not appear to correct pre-existing structural aberrations of chromosomes associated with telomere degradation, but did appear to exert a protective effect against the future development of additional chromosomal aberrations.

A human prospective cohort study conducted on a sample of 266 people over age 60 demonstrated that treatment with epithalamin, the pineal gland extract upon which epitalon is based, produced a 1.6–1.8-fold reduction in mortality during the following 6 years, a 2.5-fold reduction in mortality when combined with thymulin, and a 4.1-fold reduction in mortality when combined with thymulin and administered annually instead of only once at study onset.

Another prospective cohort study on a sample of 79 coronary patients spanning in excess of 12 years found improved metrics of physical endurance, circadian rhythm, and carbohydrate and lipid metabolism in the treated group relative to the control group following 3 years of biannual epithalamin treatments, as well as a 50% lower rate of cardiovascular mortality, a 50% lower rate of cardiovascular failure and serious respiratory disease, and a 28% lower rate of overall mortality.

Elongation of telomeres by epitalon was sufficient to surpass the Hayflick limit in a cell culture of human fetal fibroblast cells, extending their proliferative potential from termination at the 34th passage in the control cell population to beyond the 44th passage in the treated cell population, while increasing the lengths of their telomeres to levels comparable to those of cells in the original culture.

Epitalon induces decondensation of heterochromatin near the centromeres in cultured lymphocytes originating from samples taken from humans of ages 76 to 80 years.

Epitalon appears to inhibit the synthesis of the MMP9 protein in vitro in aging skin fibroblasts.

SCIENTIFICALLY INVESTIGATED POSSIBLE BENEFITS OF EPITALON
Slows the aging of cell populations by stimulating the renew and elongation of telomeres at the ends of chromosomes in DNA

Slowing of aging / anti-aging effect, rejuvenation

Prevention of cancer and age-related diseases

Restores and normalizes Melatonin production by the Pineal gland

Strong anti-oxidant properties, protects against oxidative stress, act against the effects of free radicals

Increases the activities of the antioxidant enzymes superoxide dismutase, glutathione peroxidase, and glutathione-S-transferase

Reduces lipid oxidation and ROS (reactive oxygen species) together with normalization of T cell function (increases interferon gamma production by T cells)

Better, deeper sleep and its quality

Improves metrics of physical endurance, circadian rhythm, and carbohydrate and lipid metabolism

Healthier skin, inhibits the synthesis of the MMP9 protein in vitro in aging skin fibroblasts

Positive clinical effect in Retinitis pigmentosa disease

EPITALON POSSIBLE SIDE-EFFECTS
Performed scientific studies and clinical trials to date have not shown any significant side, undesirable or toxic effects when investigating the Epitalon peptide.

EPITALON FAQ
What is Epitalon used for?
Epitalon is used for increase the natural production of telomerase, a natural enzyme that helps cells reproduce telomeres, which are the protective parts of our DNA. This ultimately leads to a slowing of the aging of cell populations, and the aging of cell populations correlate with the overall physical aging of an organism. However, epitalone can also be used to restore and normalize melatonin levels or to protect against cell oxidative stress.

Can Epitalon slow down aging?
Scientific research and performed clinical trials have demonstrated Epitalon slows the aging and has strong anti-aging properties.

Can Epitalon prevent cancer?
Yes, Epitalon has the ability to prevent cancer.

Can Epitalon improve sleep?
Yes, Epitalon supports and normalize production of Melatonin, which leads to a better and deeper sleep.

How do you administer Epitalon?
Epitalon is usually administered by intravenous, intramuscular or transdermal / subcutaneous (under the skin, through the skin) injection. Oral administration is not effective because the peptides are broken down / cleaved in the gastrointestinal tract. This means: They cannot pass through the gastrointestinal tract in functional and intact state, up to the bloodstream to exert their effects.

Where can I buy Epitalon?
We offer Epitalon of the highest purity for bargain price.

Does Epitalon have side effects?
Clinical trials to date have not shown any significant side, undesirable or toxic effects when Epitalon was used.

EPITALON DOSAGE
In the scientific studies and clinical trials performed, the optimal dose of Epitalon is often reported as 5 – 10 mg daily, over a period of 10-20 days. The frequency of administration is one injection per day at lower doses and two injections per day at higher doses, which may be divided between morning and evening. Each course of use should be followed by a pause of 4-6 months before the course is repeated

The Basics of Epitalon

What Is Epitalon?
Epitalon is a synthetic peptide made of four amino acids (alanine, glutamic acid, aspartic acid, and glycine), that is based on a natural peptide called epithalamin extracted from the pineal gland. It was synthesized by Vladimir Khavinson, a Russian professor and gerontologist, whose research focused on the development of peptide preparations used to restore function in various organs in order to prevent and reverse the aging process. He is currently the Director of the Saint Petersburg Institute of Bioregulation and Gerontology

Khavinson first extracted Epithalamin from the pineal gland of calves. However, due to the inherent limitations in production, he formulated a synthetic version of the peptide called Epitalon.

How Is Epitalon Used?
Epitalon is usually administered via intravenous or intramuscular injection or transdermally (through the skin), as peptides are broken down in the digestive tract and therefore unable to enter the bloodstream, where they can exert their effects, intact.

Although some results are promising, most of the research has been conducted in animals and cells, meaning that both the potential health benefits and safety profile of Epitalon remain largely unresearched. Never take Epitalon without consulting your doctor or use it as a replacement for approved medical therapies.

What the Research Shows for Epitalon

1) Retinitis Pigmentosa
Retinitis pigmentosa is a genetic, degenerative eye disease that results in the degeneration of the rods in the retina. Rods are one of two types of receptors in the eye (the other one being cones) that convert light into chemical signals that can be processed by the brain.In a clinical trial, Epitalon improved degenerative damage to the retina caused by this condition in 90% of the patients . In rats, Epitalon improves the function of retinal cells by preserving their structure and preventing degeneration .

A single study using humans and rats cannot be considered sufficient evidence to support this potential use of Epitalon. Further clinical research is needed to confirm these preliminary findings.

2) Correcting Circadian Rhythms
As we age, our circadian rhythms become disrupted and less pronounced, coinciding with decreased melatonin secretion and altered sleep cycles .

In a small trial on 14 elderly people, epithalamin improved melatonin production and altered its cycle and peak concentrations to resemble those of young people .

In aging monkeys, Epitalon stimulated evening melatonin secretion and reestablished the circadian rhythm, which is associated with cortisol release .

Again, only a small clinical trial and an animal study have tested this potential health benefit. Larger, more robust clinical trials are required.

Animal and Cell Research (Lack of Evidence):
No clinical evidence supports the use of Epitalon for any of the conditions listed in this section. Below is a summary of the existing animal and cell-based research, which should guide further investigational efforts. However, the studies listed should not be interpreted as supportive of any health benefit.

3) Increasing Lifespan
When the peptide was administered to fruit flies during the larval stage, it increased the average lifespan by 11-16 percent .

In a study on rats exposed to equal amounts of light and darkness, varying amounts of light and darkness, or permanent light illumination, Epitalon increased maximal lifespan in all three groups by 68 days, 95 days, and 24 days, respectively, in comparison to controls.

In mice with high blood pressure, injections of Epitalon did not affect the average lifespan of the mice but did increase the maximal lifespan by 12.3% .

Cell-based studies found that Epitalon increases telomerase activity. This enzyme adds more nucleotides to the protective sequences at the end of chromosomes (telomeres), thus allowing cells to divide and grow longer .

4) Increasing Enzyme Activity
A decrease in pancreatic enzymes has been shown to occur in elderly individuals . In both young and old rats, Epitalon increased the activity of enzymes that digest protein and sugar, with the effect being more pronounced in the older rats . Another study found that the peptide increased enzyme activity in the small intestine of aged rats [12].

5) Cancer
Below, we will discuss some preliminary research on the anticancer activity of Epitalon. It’s still in the animal stage and further clinical studies have yet to determine if this peptide is useful in cancer therapies. Do not under any circumstances attempt to replace conventional cancer therapies with Epitalon.

When Epitalon was given to rats with colon cancer, the peptide increased lymph flow (containing white blood cells) and apoptosis (programmed cell death), while it slowed cancer growth [13].

In mice with mammary tumors, Epitalon significantly decreased the number of mice with multiple tumors and decreased the maximum size of tumors in comparison to control mice [14]. The researchers also found that the peptide reduced the expression of certain genes that, when over-activated, play a key role in the development of breast cancer in both mice and humans.

Another study in mice found that treatment with Epitalon reduced the number of mice with malignant tumors (cancerous tumors) and prevented cancer from metastasizing (moving to another location in the body) in all of the treated mice. In contrast, metastases were observed in 3 out of the 9 mice that did not receive treatment with Epitalon .

Antioxidant Status
Oxidative stress, which occurs when the body has a deficit in antioxidants to counteract the effects of free radicals (damaging molecules that are missing electrons), plays a causative role in many diseases, including heart disease, cancer, diabetes, and even neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases [16].

One of the most potent antioxidants produced by the human body (endogenous antioxidants) is melatonin [17].

Epitalon’s antioxidant effects are thought to be in part due to its ability to stimulate melatonin production as well as mechanisms other than through the action of melatonin [18].

In male rats, epithalamin increased total antioxidant capacity by 36% and superoxide dismutase (SOD, a powerful endogenous antioxidant) by 19% [19].

When epithalamin was incubated with blood taken from breast cancer patients, they showed increased activity of antioxidant enzymes and levels of antioxidative vitamins [20].

Conclusion
While some preclinical studies on Epitalon look promising, there is still a lot of research that needs to be conducted in healthy and diseased individuals. Epitalon has not been approved by the FDA but is available in supplements Talk to your doctor before taking Epitalon or any other supplements, especially if they have been insufficiently researched.

About the Author:
Dr. Puya Yazdi is a physician-scientist with 14+ years of experience in clinical medicine, life sciences, biotechnology, and nutraceuticals.
As a physician-scientist with expertise in genomics, biotechnology, and nutraceuticals, he has made it his mission to bring precision medicine to the bedside and help transform healthcare in the 21st century.He received his undergraduate education at the University of California at Irvine, a Medical Doctorate from the University of Southern California, and was a Resident Physician at Stanford University. He then proceeded to serve as a Clinical Fellow of The California Institute of Regenerative Medicine at The University of California at Irvine, where he conducted research of stem cells, epigenetics, and genomics. He was also a Medical Director for Cyvex Nutrition before serving as president of Systomic Health, a biotechnology consulting agency, where he served as an expert on genomics and other high-throughput technologies. His previous clients include Allergan, Caladrius Biosciences, and Omega Protein. He has a history of peer-reviewed publications, intellectual property discoveries (patents, etc.), clinical trial design, and a thorough knowledge of the regulatory landscape in biotechnology.He is leading our entire scientific and medical team in order to ensure accuracy and scientific validity of our content and products.

Peptide BPC-157 Demonstrates Healing Effect On End Stage Kidney Disease

Two Clinical Cases Demonstrating the Healing Effects of Peptides

By Ray Schilling | Heart Disease, Hormones, kidney disease, mitochondria, regenerative medicine, stem cells

Dr. Joseph Cleaver gave a talk about two clinical cases demonstrating the healing effects of peptides. His presentation on Dec. 13, 2019 was part of the 27th Annual World Congress on Anti-Aging Medicine. The topic of his talk was “The Power of Peptides – Treatment of End Stage Renal Disease and Congestive Heart Failure, Case Studies “. Dr. Cleaver presented how his 86-year old father who had end stage kidney disease was able to go home from a palliative care facility following peptide treatment.

Next he presented another case of a 51-old man who had sustained a viral cardiomyopathy 7 years earlier. His cardiac condition had recently deteriorated, and his physicians put him on an urgent heart transplant list. After only 3 weeks of the peptide therapy he was taken off the heart transplant list as his condition had improved so much.

The medical team

Both patients received initial treatment by a conventional medical team. In the case of the 86-year old man treatment consisted of draining fluid from both lung areas and doing dialysis for chronic kidney failure. Otherwise the family received the sad news that nothing more was available to help, and he was discharged to the palliative care unit. Similarly, the 51-year old man with an end stage heart condition received conventional treatment and learned that the only other possibility to help him was a heart transplant.

The integrative medicine team that treated both patients later consisted of Dr. Mark Houston, an integrative cardiologist. In addition, there was Dr. Joseph Cleaver, one of the leaders in peptide therapy. The third person was Dr. Andrew Heyman, an expert in integrative medicine.

An 86-year old patient with end-stage kidney failure

Dr. Cleaver said that in May 2019 he received a phone call from the emergency room doctor of the hospital. He said that his father was admitted with serious heart problems and was deteriorating rapidly. He had a history of a multiple myeloma with abnormal deposits called amyloidosis. This material formed deposits in his brain and his heart muscle. As a result, he had developed a weakening of the heart resulting in fluid collection in his lungs. Just recently, on April 3, 2019 two stents were placed in his coronary arteries because of hardening of the heart vessels. He also had chronic renal failure with a very low glomerular filtration rate (GFR), which is a measure of the severity of the condition. The GFR was only 15 meaning that he needed 5 dialysis treatments per week to keep him alive.

Findings in the emergency department

An echocardiogram of the heart confirmed amyloidosis of his heart. He had an effusion around the heart, called pericardial effusion. He also had pleural effusions in both lungs. A further test confirmed kidney failure. He needed daily dialysis treatments to combat the kidney failure. The physicians removed 1600 ml of fluid from both lung cavities. Drug therapy was started to improve his heart failure. He required antibiotics for the beginning of blood poisoning (sepsis). By mid-June he had stabilized and his treatment team sent him to palliative care. The purpose of the transfer was to have another medical team look after him for end of life care.

Dr. Cleaver consulted with his integrative medicine collogues to discuss options of integrative medicine treatment of his father.

Integrative medicine approach to treat kidney failure

On June 10, 2019 the integrative medicine specialists ordered to start therapy with the peptide TB4. TB4 stands for thymosin beta 4. It can reduce infarct size in people with heart attacks. But it can also improve heart muscle function in general.

Another peptide was started on June 10, 2019, namely BPC-157. The doctors ordered this to repair organ damage.

He also received general nutraceutical supplements including the mitochondrial antioxidant MitoQuinol.

Results of integrative treatment

Dr. Cleaver’s father was able to return home in August 2019. His grip strength, gait and general strength were the best he has been in years. He returned to wood working (building furniture). He lifts weights and uses an exercise bike every day. His chronic lower back pain has mostly disappeared. His gait is strong and his balance has improved. He maintains his kidney function with only one dialysis treatment per week. He is looking after his garden, walks without assistance and enjoys spending time with his wife. His heart function has normalized and there is significant improvement in his kidney function.

A 51-old man with viral cardiomyopathy waiting for a heart transplant

The second clinical case that Dr. Cleaver presented was that of a 51-year old man who had contracted a viral cardiomyopathy 7 years earlier. His heart function had slowly deteriorated since then. The doctors had nothing else to offer him with his heart condition except to put him on a waiting list for a heart transplant. His symptoms were shortness of breath and fatigue. In addition he required two pillows for sleeping to cope with his shortness of breath.

Integrative medicine approach to treat heart failure

Here is what the treatment plan from the integrative medicine team for this patient included.

The team concentrated on heart muscle cell regeneration and reconditioning of the cardiac mitochondria. The main peptides used were BPC-157 and thymosin beta 4. Another peptide was Ipamorelin, which is known to release growth hormone. Human growth hormone has been shown to improve heart function in patients with heart failure.

The doctors also ordered CoQ-10 and MitoQuinol to stimulate the mitochondria of the heart muscle. In their search for effective alternative remedies for cardiomyopathy the integrative medicine team found supportive literature. They found that growth hormone releasing hormone and Ipamorelin were stimulating receptors on cardiac stem cells. This stimulates survival of heart muscle fibers and modulates genes that regulate cardiac remodelling. The team also administered Hexarelin and ghrelin, which release growth hormone in the body.

Within only three weeks this patient’s shortness of breath disappeared. His ejection fraction, a measure of left heart chamber contraction normalized. He felt energy and no longer needed two pillows to sleep. Due to his improvement his doctor took him off the heart transplant list.

Discussion

These two cases demonstrate the limits of conventional medicine. Chronic kidney failure and chronic heart failure are conditions for which the normal health care system has no answers. But interestingly, the integrative medicine team managed using innovative peptides that helped in both of these cases. Dr. Cleaver reminded us that we should not only trust in conventional medicine, particularly when there is no positive result. Integrative medicine can offer alternative approaches for the difficult cases that conventional medicine cannot solve. At this point we do not know all the mechanisms of why peptides are helping. Some papers point out that peptides may stimulate pluripotent stem cells to heal whatever condition it is in the body. Dr. Cleaver provided extensive literature references regarding several peptides that are now in clinical use.

Two Clinical Cases Demonstrating the Healing Effects of Peptides

Conclusion

Dr. Cleaver gave a talk about peptides at the 27th Annual World Congress on Anti-Aging Medicine on Dec. 13, 2019. He presented two clinical examples, which could not be dealt with by conventional medicine. The first was an 86-year old patient with end-stage kidney failure. The second was a 51-old man with viral cardiomyopathy waiting for a heart transplant. Miraculously, both cases responded to peptide therapy with TB4 (thymosin beta 4) and BPC157. Within a matter of a few weeks there was clinical improvement in both cases. The 86-year old man could return home from a palliative care home, attend to his garden and do woodworking. The 51-year old man regained his cardiac strength and his physician took him off the heart transplant list. Integrative medicine can be useful in chronic cases that conventional medicine cannot improve.

Peptides are proving to be the cutting edge healing modalities of the 21st century. If you have any question about how you can further your research into peptides please contact me and I will forward more in depth information to you

Blessings, Bobby

New Peptide Science Targets Breast Cancer Cells

Being able to target Breast Cancer cells, with peptides specifically designed to identify and destroy breast cancer cells is beginning to gain a foothold as a highly efficient approach to selectively deliver targeted destruction to cancer cells with minimal cellular toxicity.

Even the highly aggressive form of breast cancer HER2+ is being down regulated by the utilization of peptide enhanced therapies.. The new polymalic acid-based mini nanodrugsare peptides are synthesized and specifically characterized to inhibit growth of HER2+ breast cancer. These mini nanodrugs are highly effective and may soon be able to be substituted for Trastuzumab.  The addition of the peptides have caused the HER2+ cells to be recognized, targeted and destroyed by the polymer-attached trastuzumab-mimetic 12-mer peptide at a faster and safer rate than ever, preventing cancer cell proliferation and and causing a significant reduction in tumor size by more than 15 times vs. untreated control group.

Cancer Targeting Peptides – Not to be used on human beings. These Peptides are for research purposes only. I do not have a financial interest in the company or any affiliation. Robert Morgan, ND

https://cpcscientific.com/product-category/research-area/cancer/

%d